Ontology highlight
ABSTRACT:
SUBMITTER: Madhulika Mishra
PROVIDER: MODEL1808060001 | BioModels | 2019-08-07
REPOSITORIES: BioModels
Action | DRS | |||
---|---|---|---|---|
MODEL1808060001?filename=Supplementary3.zip | Other |
Items per page: 5 1 - 1 of 1 |
Mishra Madhulika M Jayal Priyanka P Karande Anjali A AA Chandra Nagasuma N
The FEBS journal 20180906 21
Sorafenib (SFB), a multi-kinase inhibitor, is the only approved drug for treating hepatocellular carcinoma (HCC). However, SFB shows low efficacy in many cases. HCC related mortality therefore remains to be high worldwide. SFB, a multi-kinase inhibitor is also known to modulate the redox homeostasis in cancer cells. To understand the effect of SFB on the redox status, a quantitative understanding of the system is necessary. Kinetic modeling of the relevant pathways is a useful approach for obtai ...[more]